FIELD: medicine.
SUBSTANCE: invention refers to stable metastin derivatives exhibiting biological activity related to cancer metastasis suppression, cancer cell growth supression, gonadotrophin secretion stimulation and sex hormone stimulation.
EFFECT: replacement of amino acids being the ingredients of metastin by certain amino acids in the produced metastin derivative according to the invention provides better stability, blood solubility, reduced tendency to gel formation, improved pharmacokinetic values.
15 cl, 3 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METASTIN DERIVATIVES AND USE THEREOF | 2007 |
|
RU2454425C2 |
| PEPTIDE COMPOSITIONS | 2014 |
|
RU2725150C2 |
| METHOD (VERSIONS) AND PREPARATION FOR MODIFICATION OF EATING BEHAVIOUR | 2002 |
|
RU2519748C2 |
| ANALOGUES OF PEPTIDE LH-RF, THEIR APPLICATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF | 1998 |
|
RU2212247C2 |
| α-CYCLODEXTRIN-BASE PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION OF ANALOGS OF RELEASING-HORMONE OF LUTEINIZING HORMONE (LH-RH) | 1999 |
|
RU2214270C2 |
| NEUROMEDIN AND SOMATOSTATIN RECEPTOR AGONISTS | 2000 |
|
RU2263680C2 |
| PEPTIDIC INTERLEUKIN-23 RECEPTOR INHIBITORS FOR ORAL ADMINISTRATION AND USE THEREOF FOR TREATING INFLAMMATORY INTESTINAL DISEASES | 2015 |
|
RU2736637C2 |
| PRODRUG COMPOSITIONS WITH HIGH DEGREE OF PENETRATION BASED ON PEPTIDES AND RELATED COMPOUNDS | 2010 |
|
RU2627065C2 |
| APPLICATION OF MELANOCORTIN FOR TREATING INSULIN SENSITIVITY | 2008 |
|
RU2453328C2 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
